Niagen Bioscience, Inc. reported significant financial growth in its latest 10-K filing for the fiscal year ending December 31, 2025. The company achieved net sales of approximately $129.4 million, a 30% increase from $99.6 million in 2024. This growth was primarily driven by a 27% rise in sales of its flagship product, Tru Niagen®, which generated $97.7 million in revenue. The Ingredients segment also saw a notable increase, with sales rising 45% to $28.7 million, reflecting strong demand for both food-grade and pharmaceutical-grade Niagen® products.
The company’s profitability improved markedly, with net income reaching $17.4 million, compared to $8.6 million in the previous year, marking a 103% increase. This improvement was attributed to higher gross profit, which rose to $83.2 million, up from $61.6 million in 2024, resulting in a gross margin of 64.3%. Operating expenses increased to $66.9 million, driven by higher sales and marketing costs, but the overall operating income still improved to $16.3 million from $7.7 million in 2024.
Strategically, Niagen Bioscience made significant moves, including the acquisition of patent rights from Queen’s University Belfast, which eliminated future royalty obligations and resulted in a $2 million gain. The company also announced plans to sell its analytical reference standards and services segment, classifying these assets as held for sale, which is expected to streamline operations and focus on its core business segments. As of December 31, 2025, the company had approximately 117 full-time employees, reflecting its commitment to maintaining a skilled workforce to support its growth.
Operationally, Niagen Bioscience has expanded its geographic reach, with international sales contributing over 10% of total revenue, particularly in the Asia-Pacific region. The company has also established a robust e-commerce platform, which has been a key driver of sales growth. The filing indicates that the company is well-positioned for future growth, with a strong cash position of $64.8 million and no outstanding borrowings under its line of credit, providing a solid foundation for ongoing operations and potential investments.
Looking ahead, Niagen Bioscience expressed optimism about its growth trajectory, driven by increasing consumer demand for its products and the expanding market for dietary supplements. The company plans to continue investing in research and development to enhance its product offerings and maintain its competitive edge in the bioscience sector. However, it also acknowledged potential risks, including regulatory changes and market competition, which could impact future performance.
About Niagen Bioscience, Inc.
ChromaDex is a bioscience company focused on healthy aging, developing and commercializing proprietary NAD+ precursors like Niagen. Its core segments include consumer dietary supplements, ingredient technologies for food and pharma, and analytical standards for quality control. The company emphasizes scientific research, global distribution, and intellectual property to support innovative products aimed at enhancing cellular health and longevity.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.